Search results
Pharma Stock Roundup: FDA Nod to MRK's New Jab & Expanded Use of ABBV & AZN Drugs
Zacks via Yahoo Finance· 3 days agoFDA approves Merck's (MRK) 21-valent pneumococcal conjugate vaccine, Capvaxive and the expanded use...
M&R Capital Management Inc. Has $2.84 Million Holdings in AbbVie Inc. (NYSE:ABBV)
ETF DAILY NEWS· 5 days agoM&R Capital Management Inc. reduced its position in AbbVie Inc. (NYSE:ABBV – Free Report) by 0.6% during the 1st quarter, according to the company in its most recent filing with the Securities ...
States struggle to help patients navigate insurance hurdle known as ‘step therapy’
North Dakota Monitor via Yahoo News· 1 day agoCassidy Yermal, 32, began experiencing debilitating migraines when she was 17 years old. As a...
Did Teva Pharmaceutical Industries Limited (TEVA)’s “Pivot to Growth” Strategy Help It Get a...
Insider Monkey via Yahoo Finance· 2 days agoWe recently compiled a list of the 10 Best Robinhood Stocks Under $20. In this article, we are going...
239 Shares in AbbVie Inc. (NYSE:ABBV) Bought by Ables Iannone Moore & Associates Inc.
ETF DAILY NEWS· 6 days agoAbles Iannone Moore & Associates Inc. bought a new stake in AbbVie Inc. (NYSE:ABBV – Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities ...
AbbVie's (ABBV) Skyrizi Gets FDA Nod for Ulcerative Colitis
Zacks via Yahoo Finance· 5 days agoThe studies also achieved a key secondary endpoint of endoscopic improvement. Skyrizi is already...
Psoriasis: Features That May Affect Biologic Rx Outcomes
Medscape· 7 days agoSeveral clinical characteristics were negatively associated with responses to biologics in a...
A New Psychotherapeutic 'Gold Standard' for Chronic Pain?
Medscape· 6 days agoA single course of treatment with emotional awareness and expression therapy (EAET) was associated...
Certain Clinical Factors Tied to Poor Response to Biologics for Psoriasis
MedPage Today· 7 days agoPrevious exposure to biologics, higher BMI, smoking all negatively linked to response
J&J (JNJ) Seeks Expanded Use of Tremfya for Crohn's Disease
Zacks· 4 days agoJ&J (JNJ) seeks label expansion for Tremfya for treating moderately to severely active Crohn's disease. This marks the second sBLA filing for Tremfya in three months.